Healthcare (Basel, Switzerland)
Paul Shafer, assistant professor of health law, policy & management at SPH
Note : Many people with arrhythmias do not experience any symptoms
In addition, superiority was seen for death from any cause for liraglutide in LEADER (HR 0.85 [95% CI: 0.740.97]) and for the expanded composite endpoint of CV death, nonfatal MI, nonfatal stroke, revascularization, and hospitalization for unstable angina or HF with sc semaglutide in SUSTAIN 6 (HR 0.74 [95% CI: 0.620.89])
However, there was no difference between the treatment and placebo groups regarding the maximal oxygen consumption and composition
Its essential to stay consistent with your medication and communicate any concerns with your healthcare provider